Roles of a prostaglandin E‐type receptor, EP3, in upregulation of matrix metalloproteinase‐9 and vascular endothelial growth factor during enhancement of tumor metastasis

Cyclooxygenase (COX)‐2 is known to correlate with poor cancer prognosis and to contribute to tumor metastasis. However, the precise mechanism of this phenomenon remains unknown. We have previously reported that host stromal prostaglandin E 2 (PGE 2 )–prostaglandin E2 receptor (EP)3 signaling appears critical for tumor‐associated angiogenesis and tumor growth. Here we tested whether the EP3 receptor has a critical role in tumor metastasis. Lewis lung carcinoma (LLC) cells were intravenously injected into WT mice and mice treated with the COX‐2 inhibitor NS‐398. The nonselective COX inhibitor aspirin reduced lung metastasis, but the COX‐1 inhibitor SC560 did not. The expression of matrix metalloproteinases (MMP)‐9 and vascular endothelial growth factor (VEGF)‐A was suppressed in NS‐398‐treated mice compared with PBS‐treated mice. Lungs containing LLC colonies were markedly reduced in EP3 receptor knockout (EP3 −/− ) mice compared with WT mice. The expression of MMP‐9 and VEGF‐A was downregulated in metastatic lungs of EP3 −/− mice. An immunohistochemical study revealed that MMP‐9‐expressing endothelial cells were markedly reduced in EP3 −/− mice compared with WT mice. When HUVEC were treated with agonists for EP1, EP2, EP3, or EP4, only the EP3 agonist enhanced MMP‐9 expression. These results suggested that EP3 receptor signaling on endothelial cells is essential for the MMP‐9 upregulation that enhances tumor metastasis and angiogenesis. An EP3 receptor antagonist may be useful to protect against tumor metastasis. ( Cancer Sci 2009; 100: 2318–2324)